Xenetic Biosciences Inc
XBIO2.230USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.44MMarket Cap
LossP/E TTM
More Details of Xenetic Biosciences Inc Company
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Xenetic Biosciences Inc Info
Ticker SymbolXBIO
Company nameXenetic Biosciences Inc
IPO dateNov 07, 2016
CEOParslow (James F)
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 07
Address945 Concord St.
CityFRAMINGHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01701
Phone17817787720
Websitehttps://www.xeneticbio.com/
Ticker SymbolXBIO
IPO dateNov 07, 2016
CEOParslow (James F)
Company Executives of Xenetic Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dmitry Dmitrievich Genkin, M.D.
Dr. Dmitry Dmitrievich Genkin, M.D.
Director
Director
68.46K
--
Mr. Moshe Mizrahy
Mr. Moshe Mizrahy
Director
Director
--
--
Dr. Alexey Vinogradov
Dr. Alexey Vinogradov
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. James F. (Jim) Parslow
Mr. James F. (Jim) Parslow
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
--
--
Dr. Grigory G. Borisenko, Ph.D.
Dr. Grigory G. Borisenko, Ph.D.
Independent Director
Independent Director
--
--
Mr. Firdaus Jal Dastoor
Mr. Firdaus Jal Dastoor
Independent Director
Independent Director
--
--
Dr. Roger D. Kornberg, Ph.D.
Dr. Roger D. Kornberg, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dmitry Dmitrievich Genkin, M.D.
Dr. Dmitry Dmitrievich Genkin, M.D.
Director
Director
68.46K
--
Mr. Moshe Mizrahy
Mr. Moshe Mizrahy
Director
Director
--
--
Dr. Alexey Vinogradov
Dr. Alexey Vinogradov
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. James F. (Jim) Parslow
Mr. James F. (Jim) Parslow
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
--
--
Dr. Grigory G. Borisenko, Ph.D.
Dr. Grigory G. Borisenko, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CLS Therapeutics, Ltd.
6.44%
Genkin (Dmitry Dmitrievich)
2.99%
Renaissance Technologies LLC
1.26%
Vinogradov (Alexey Andreevich)
0.82%
Sachetta, LLC
0.67%
Other
87.83%
Shareholders
Shareholders
Proportion
CLS Therapeutics, Ltd.
6.44%
Genkin (Dmitry Dmitrievich)
2.99%
Renaissance Technologies LLC
1.26%
Vinogradov (Alexey Andreevich)
0.82%
Sachetta, LLC
0.67%
Other
87.83%
Shareholder Types
Shareholders
Proportion
Corporation
6.44%
Individual Investor
4.07%
Hedge Fund
1.26%
Investment Advisor
1.10%
Investment Advisor/Hedge Fund
0.47%
Other
86.67%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
21
70.94K
3.12%
-50.75K
2025Q2
30
416.13K
26.98%
+12.54K
2025Q1
36
412.01K
26.72%
-933.00
2024Q4
36
393.92K
25.54%
+18.73K
2024Q3
34
352.79K
22.89%
+17.12K
2024Q2
31
318.94K
20.69%
-45.34K
2024Q1
31
323.67K
21.00%
-37.99K
2023Q4
34
303.91K
19.80%
+10.04K
2023Q3
37
285.57K
18.68%
-66.63K
2023Q2
36
249.73K
16.47%
-88.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
CLS Therapeutics, Ltd.
147.50K
9.56%
--
--
Mar 31, 2025
Genkin (Dmitry Dmitrievich)
68.46K
4.44%
--
--
Mar 31, 2025
Renaissance Technologies LLC
24.75K
1.6%
-2.01K
-7.53%
Jun 30, 2025
Vinogradov (Alexey Andreevich)
18.68K
1.21%
--
--
Mar 31, 2025
Sachetta, LLC
15.26K
0.99%
+4.59K
+43.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
10.48K
0.68%
-475.00
-4.34%
Jun 30, 2025
The Vanguard Group, Inc.
6.73K
0.44%
--
--
Aug 31, 2025
Maguire (Michael Scott)
6.00K
0.39%
--
--
Mar 18, 2024
JTC Employer Solutions Trusteee Ltd
2.70K
0.18%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
Date
Type
Ratio
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
May 12, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Xenetic Biosciences Inc?
The top five shareholders of Xenetic Biosciences Inc are:
CLS Therapeutics, Ltd. holds 147.50K shares, accounting for 9.56% of the total shares.
Genkin (Dmitry Dmitrievich) holds 68.46K shares, accounting for 4.44% of the total shares.
Renaissance Technologies LLC holds 24.75K shares, accounting for 1.60% of the total shares.
Vinogradov (Alexey Andreevich) holds 18.68K shares, accounting for 1.21% of the total shares.
Sachetta, LLC holds 15.26K shares, accounting for 0.99% of the total shares.
CLS Therapeutics, Ltd. holds 147.50K shares, accounting for 9.56% of the total shares.
Genkin (Dmitry Dmitrievich) holds 68.46K shares, accounting for 4.44% of the total shares.
Renaissance Technologies LLC holds 24.75K shares, accounting for 1.60% of the total shares.
Vinogradov (Alexey Andreevich) holds 18.68K shares, accounting for 1.21% of the total shares.
Sachetta, LLC holds 15.26K shares, accounting for 0.99% of the total shares.
What are the top three shareholder types of Xenetic Biosciences Inc?
The top three shareholder types of Xenetic Biosciences Inc are:
CLS Therapeutics, Ltd.
Genkin (Dmitry Dmitrievich)
Renaissance Technologies LLC
CLS Therapeutics, Ltd.
Genkin (Dmitry Dmitrievich)
Renaissance Technologies LLC
How many institutions hold shares of Xenetic Biosciences Inc (XBIO)?
As of 2025Q3, 21 institutions hold shares of Xenetic Biosciences Inc, with a combined market value of approximately 70.94K, accounting for 3.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -23.87%.
What is the biggest source of revenue for Xenetic Biosciences Inc?
In --, the -- business generated the highest revenue for Xenetic Biosciences Inc, amounting to -- and accounting for --% of total revenue.
